First AD

Second AD

Ibrahim Aldoss, MD, is an associate professor in the Division of Leukemia in the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope

Shira Dinner, MD, is an associate professor in the Feinberg School of Medicine at Northwestern University.

Shira Dinner, MD, and Ibrahim Aldoss, MD, discuss the addition of blinatumomab to the CALGB 10403 regimen in MRD-negative acute lymphoblastic leukemia.

Blinatumomab Plus CALGB 10403 in ALL

OncLive News Network®

® video programs provide lively discussions, insights, and expert perspectives on important issues facing today’s cancer care professionals. One variation of the program, titled, 

, comprises live virtual or on-site premium reporting for oncologists as it covers the latest news and information coming out of the largest annual oncology conferences. 

Hematologic Oncology

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Adding Blinatumomab to the CALGB 10403 Regimen in B-Cell Precursor ALL in MRD-Negative Remission